Current News
May 8, 2008
Znomics and University of Utah Launch Collaborative Drug Discovery Program
Znomics announced a collaborative research program with the University of Utah and its Huntsman Cancer Institute (HCI) to develop pre-clinical compounds for the treatment of T-cell leukemia, autoimmune diseases, inflammation and complications related to organ transplantation. [Read the complete press release...]
April 16, 2008
Znomics Launches Drug Discovery Program in Obesity Using Proprietary In Vivo Screening Model
Znomics announced the launch of a program to find lead drug compounds for the treatment of obesity. [Read the complete press release...]
March 6, 2008
Znomics Appoints Stephane Berghmans, D.V.M., Ph.D. to Director of Drug Discovery
Znomics announced the appointment of Stephane Berghmans, D.V.M., Ph.D. to Director of Drug Discovery, effective March 10, 2008. [Read the complete press release...]
February 25, 2008
Znomics Expands Drug Discovery Facilities
Znomics announced that it has expanded its facilities to include additional laboratory space in the new Biomedical Research Building on the campus of Oregon Health and Science University (OHSU) in Portland. [Read the complete press release...]
February 14, 2008
Znomics Promotes Stephen Kurtz, Ph.D. to Director of Operations
Znomics announced the promotion of Stephen Kurtz, Ph.D. to director of operations, effective March 1, 2008. As director of operations, reporting to the chief executive officer and chief scientific officer, Kurtz will be responsible for expanding Znomics’ drug discovery program by evaluating new technologies, at universities and companies, for possible in-licensing opportunities. Additionally, he will oversee some laboratory operations as well as liaise with university and corporate scientists that engage in collaborative programs with Znomics. [Read the complete press release...]
February 12, 2008
Znomics Retains James Posada as Business Advisor
Znomics announced that it has retained James Posada, Ph.D., as a business advisor to assist with business development, effective immediately. Posada’s initial mission will be to help with the development of collaborative programs with potential pharmaceutical and biotechnology partners. Additionally, he will oversee technology in-licensing and out-licensing activities for Znomics. [Read the complete press release...]
February 6, 2008
Znomics Advances Drug Discovery Efforts in Zebrafish With Launch of New Human Disease Library
Znomics announced that it has achieved mutations in 193 key genes, representing nearly 50 percent of the known “druggable” disease genes. The company expects that information derived from these disrupted genes and others from its ZeneMark® library of mutant fish lines will advance its search for new drug targets and new lead compounds for complex human diseases. [Read the complete press release...]
January 23, 2008
Znomics Appoints Thomas Scanlan, Professor of Pharmacology, to Scientific Advisory Board
Professor Scanlan’s leading work in drug compound discovery and biological research has been recognized by the American Chemical Society, which awarded him the prestigious Arthur C. Cope Scholar Award in July, 2007. His appointment expands Znomics’s SAB to five members. [Read the complete press release...]
January 4, 2008
Znomics, Inc. Begins Trading Under New Ticker Symbol -- ZNOM.OB
Znomics announced that its common stock will begin trading on the OTC Bulletin Board under the new ticker symbol, “ZNOM.OB”, effective today, Friday, January 4, 2008. [Read the complete press release...]
© Copyright Znomics, Inc. All rights reserved.